Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS: We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with intermediate or poor prognostic risk. RESULTS: A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422, respectively, had intermediate or poor risk. At a median follow-up of 25.2 months in intermediate- and poor-risk patients, the 18-month overall survival rate was 75% (95% confidence interval [CI], 70 to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with sunitinib; the median overall survival was not reached with nivolumab plus ipilimumab versus 26.0 months with sunitinib (hazard ratio for death, 0.63; P<0.001). The objective response rate was 42% versus 27% (P<0.001), and the complete response rate was 9% versus 1%. The median progression-free survival was 11.6 months and 8.4 months, respectively (hazard ratio for disease progression or death, 0.82; P=0.03, not significant per the prespecified 0.009 threshold). Treatment-related adverse events occurred in 509 of 547 patients (93%) in the nivolumab-plus-ipilimumab group and 521 of 535 patients (97%) in the sunitinib group; grade 3 or 4 events occurred in 250 patients (46%) and 335 patients (63%), respectively. Treatment-related adverse events leading to discontinuation occurred in 22% and 12% of the patients in the respective groups. CONCLUSIONS: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“In that study, patients were randomized either to that regimen or to sunitinib (a VEGF inhibitor); significant prolongation of PFS and overall survival was observed, with 42% of patients achieving a response (many of these durable)11,12.”
From Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial (2022) · cites this paper as [11]
In the citing paper
“Anti-PD-1/PD-L1 agents pared with chemotherapy have also improved response rates and survival in many diseases including lung cancer, triple negative breast cancer, head and neck squamous cell carcinoma, and others.12–14”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Self-citationSunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775 · cited 1×
“Diarrhea 145 (27) 21 (4) 278 (52) 28 (5)”
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 4×
“Female 111 (26) 121 (29) 137 (25) 151 (28)”
InfluentialTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Decreased appetite 75 (14) 7 (1) 133 (25) 5 (<1)”
Cited by
Items 801–900 of 1,016
Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions
Rafii, S., Mukherji, D., Komaranchath, A. S., Khalil, C., Iqbal, F., Abdelwahab, S. İ., Abyad, A. M., Abuhelwa, A. Y., Gandikota, L., & Al-Shamsi, H. O. (2025) · Cancers · doi:10.3390/cancers17172898 · Cited by 48
Check point inhibitors a new era in renal cell carcinoma treatment
Alsharedi, M. F., & Katz, H. (2018) · Medical Oncology · doi:10.1007/s12032-018-1147-y · Cited by 40
Brown, M. P., Ebert, L. M., & Gargett, T. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1050 · Cited by 46
“response rates of at least 40%, which translate to substantially enhanced survival prospects.(14,15) The same combination therapy provides comparable beneficial effects in patients with melanoma brain metastases,(16,17) yet ICI therapy has had little beneficial clinical impact in glioblastoma patients.”
BackgroundBuilding on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer
Garces, A. I., Au, L., Mason, R., Thomas, J. M., & Larkin, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1649657 · Cited by 42
“mRCC through phase III clinical trial as a single agent [91] and more recently in combination with ipilimumab [21].”
BackgroundOn the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment
Tundo, G. R., Sbardella, D., Lacal, P. M., Graziani, G., & Marini, S. (2019) · Chemotherapy · doi:10.1159/000500902 · Cited by 44
Efuni, E., Cytryn, S. L., Boland, P. M., Niewold, T. B., Pavlick, A. C., Weber, J. S., & Sandigursky, S. (2020) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001314 · Cited by 42
“Etanercept 1 (5) Sulfasalazine 2 (9) Intravenous immunoglobulin 1 (1)”
BackgroundInfluentialKawashima, A., Kanazawa, T., Kidani, Y., Yoshida, T., Hirata, M., Nishida, K., Nojima, S., Yamamoto, Y., Kato, T., Hatano, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63060-1 · Cited by 45
Organoid technology and applications in cancer immunotherapy and precision medicine
Homicskó, K. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.05.002 · Cited by 40
Chau, V., & Bilušić, M. (2020) · Cancer Management and Research · doi:10.2147/cmar.s216605 · Cited by 46
Gan, C. L., Dudani, S., Wells, J. C., Donskov, F. N., Pal, S. K., Dizman, N., Rathi, N., Beuselinck, B., Yan, F., Lalani, A. A., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3717 · Cited by 40
Self-citationIf small molecules immunotherapy comes, can the prime be far behind?
Zhang, J., Zhang, Y., Qu, B., Yang, H., Hu, S., & Dong, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113356 · Cited by 40
Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity
Burton, E. M., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0257 · Cited by 40
Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies
Yang, W., Lei, C., Song, S., Jing, W., Jin, C., Gong, S., Tian, H., & Guo, T. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02299-8 · Cited by 43
“CheckMate-214 [42] investigated the addition of nivolumab to ipilimumab as the first-line treatment of RCC.”
BackgroundDong, K., Chen, W., Pan, X., Wang, H., Sun, Y., Qian, C., Chen, W., Wang, C., Fu, Y., & Cui, X. (2022) · BMC Cancer · doi:10.1186/s12885-022-09251-7 · Cited by 44
“Clinical trials of immune checkpoint inhibitor (ICI) versus TKI treatment for ccRCC, such as CheckMate 214 [5], CheckMate 9ER [6], Keynote-426 [7], and IMmotion 151 [8] have shown pronounced clinical benefits.”
MethodHasanov, E., Yeboa, D. N., Tucker, M. D., Swanson, T. A., Beckham, T. H., Rini, B. I., Ene, C., Hasanov, M., Derks, S. H. A. E., Smits, M., et al. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21729 · Cited by 55
Self-citationCarlisle, J. W., Jansen, C. S., Cardenas, M. A., Sobierajska, E., Reyes, A. M., Greenwald, R., del Balzo, L., Prokhnevska, N., Küçük, Ö., Carthon, B. C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004803 · Cited by 46
Aldin, A., Besiroglu, B., Adams, A., Monsef, I., Piechotta, V., Tomlinson, E., Hornbach, C., Dressen, N., Goldkuhle, M., Maisch, P., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013798.pub2 · Cited by 51
Virumbrales-Muñoz, M., Chen, J., Ayuso, J., Lee, M., Abel, E. J., & Beebe, D. J. (2020) · Lab on a Chip · doi:10.1039/d0lc00252f · Cited by 39
“PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer
Bell, H. N., Cotta, B. H., Salami, S. S., Kim, H. L., & Vaishampayan, U. N. (2021) · Kidney Cancer · doi:10.3233/kca-210010 · Cited by 42
“The study Checkmate 214 established superior efficacy of ipilimumab (ipi) plus nivolumab (nivo) over sunitinib, demonstrating OS benefit for patients with previously untreated metastatic renal cancer [11].”
BackgroundInfluentialVerhoeff, S. R., Oosting, S. F., Elias, S. G., van Es, S. C., Gerritse, S. L., Angus, L., Heskamp, S., Desar, I. M. E., van Oordt, C. W. M. D. H., van der Veldt, A. A. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0921 · Cited by 41
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab
McQuade, J. L., Hammers, H. J., Furberg, H. F., Engert, A., André, T., Blumenschein, G. R., Tannir, N. M., Baron, A. D., Larkin, J., El-Khoueiry, A. B., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5409 · Cited by 41
Self-citationImmunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm
Baas, I. O., Westermann, A. M., You, B., Bolze, P., Seckl, M. J., & Ghorani, E. (2023) · Gynecologic and Obstetric Investigation · doi:10.1159/000533972 · Cited by 39
“…agents targeting inhibitory T cell receptors including programmed cell death 1 (PD-1) and its ligand (PD-L1) and cytotoxic T-lymphocyte associated antigen 4, have revolutionised the treatment of several types of cancer such as melanoma [6], non-small cell lung cancer [7] and renal cell cancer [8].”
BackgroundJasti, J., Zhong, H., Panwar, V., Jarmale, V. N., Miyata, J., Carrillo, D., Christie, A., Rakheja, D., Modrusan, Z. D., Kadel, E. E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57717-6 · Cited by 44
“However, it is unclear whether ICI and AA are truly synergistic 37 and there is evidence suggesting that tumors respond predominantly to one or the other 3 – 5 .”
Sim, E. S., Nguyen, H. C. B., Hanna, G. J., & Uppaluri, R. (2025) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2024.5254 · Cited by 43
Antibody-lectin chimeras for glyco-immune checkpoint blockade
Stark, J. C., Gray, M. A., Ibarlucea-Benitez, I., Lustig, M., Bond, A., Cho, B., Govil, I., Luu, T., Priestley, M. J., Veth, T. S., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02884-6 · Cited by 54
“MVsim 55 , a multivalent binding simulation application (v.1.1 with MAT-LAB 2021a), was used to model the binding of trastuzumab, T7 AbLec, T7A mutant AbLec and Siglec-7-Fc to K562-HER2 cells.”
InfluentialWei, Y., Du, Q., Jiang, X., Li, L., Li, T., Li, M., Fan, X., Li, Y., Kariminia, S., & Li, Q. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.04.008 · Cited by 41
Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma
Kahlmeyer, A., Stöhr, C., Hartmann, A., Goebell, P. J., Wullich, B., Wach, S., Taubert, H. W., & Erlmeier, F. (2018) · Journal of Clinical Medicine · doi:10.2139/ssrn.3284851 · Cited by 46
Hwang, I., Park, I., Yoon, S., & Lee, J. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.09.009 · Cited by 41
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
Wakabayashi, G., Lee, Y., Luh, F., Kuo, C.-N., Chang, W., & Yen, Y. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0588-8 · Cited by 40
Debien, V., Thouvenin, J., Lindner, V., Barthélémy, P., Lang, H., Flippot, R., & Malouf, G. G. (2019) · Cancers · doi:10.3390/cancers12010099 · Cited by 41
“and avelumab plus axitinib [47] demonstrated PFS improvement compared to sunitinib in the first-line metastatic setting.”
BackgroundSelf-citationFaury, S., & Foucaud, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227344 · Cited by 44
“Results of HRQOL data are not presented in the main papers of these 13 RCTs [36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48].”
BackgroundGrimm, M., Leucht, K., Grünwald, V., & Foller, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020565 · Cited by 42
“Additionally, on account of CheckMate 214 [5], for patients with intermediate or poor”
BackgroundInfluentialSelf-citationImmune evasion in renal cell carcinoma: biology, clinical translation, future directions
Wang, X., Lopez, R., Luchtel, R. A., Hafizi, S., Gartrell, B. A., & Shenoy, N. K. (2020) · Kidney International · doi:10.1016/j.kint.2020.08.028 · Cited by 43
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
Tripathi, A., Lin, E., Xie, W., Flaifel, A., Steinharter, J. A., Gatof, E. S., Bouchard, G., Fleischer, J. H., Chanzá, N. M., Gray, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001467 · Cited by 44
Self-citationNon-clear cell renal carcinomas: Review of new molecular insights and recent clinical data
Barthélémy, P., Rioux-Leclercq, N. C., Thibault, C., Saldana, C., Borchiellini, D., Chevreau, C., Desmoulins, I., Gobert, A., Hilgers, W., Khalil, A., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102191 · Cited by 43
Self-citationIinuma, K., Enomoto, T., Kawada, K., Fujimoto, S., Ishida, T., Takagi, K., Nagai, S., Ito, H., Kawase, M., Nakai, C., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10225325 · Cited by 41
“In other recent randomized phase III trials (Checkmate 214 [4], KEYNOTE-426 [5], JAVELIN Renal 101 [6], IMmotion151 [7], and CheckMate 9ER [8]), combining ICI and/or TKI therapies reportedly affords greater clinical benefits, especially in terms of oncological outcomes, than NIVO or TKI monotherapy…”
Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review
Lalani, A. A., Heng, D. Y. C., Basappa, N. S., Wood, L. A., Iqbal, N., McLeod, D., Soulières, D., & Kollmannsberger, C. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221108685 · Cited by 41
Self-citationJammihal, T., Saliby, R. M., Labaki, C., Soulati, H., Gallegos, J., Peris, A., McCurry, D., Yu, C., Shah, V., Poduval, D., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00896-w · Cited by 38
“CM-214 is a phase 3 clinical trial that investigated the effectiveness and safety of combination therapy with nivolumab and ipilimumab versus sunitinib in previously untreated participants with advanced or mRCC 3,43 .”
Self-citationGed, Y. M. A., Sánchez, A., Patil, S., Knežević, A., Stein, E., Petruzella, S., Weiss, K. L., Düzgöl, C., Chaim, J. L., Akın, O., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1389 · Cited by 39
Self-citationAlhalabi, O., Thouvenin, J., Négrier, S., Vano, Y. A., Campedel, L., Hasanov, E., Bakouny, Z., Hahn, A. W., Bilen, M. A., Msaouel, P., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyac262 · Cited by 38
Self-citationManagement of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic
Lyskjær, I., Iisager, L., Axelsen, C. T., Nielsen, T. K., Dyrskjøt, L., & Fristrup, N. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1892 · Cited by 45
Yanagisawa, T., Mori, K., Matsukawa, A., Kawada, T., Katayama, S., Bekku, K., Laukhtina, E., Rajwa, P., Quhal, F., Pradère, B., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03621-1 · Cited by 41
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
Yamada, K., Takeuchi, M., Fukumoto, T., Suzuki, M., Kato, A., Mizuki, Y., Yamada, N., Kaneko, T., Mizuki, N., & Horita, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-55675-5 · Cited by 43
“The nivolumab plus ipilimumab, the most frequently selected dual ICI therapy, is considered first-line therapy for renal cell carcinoma 12 , non-small cell lung cancer 13 , esophageal cancers 14 , colorectal cancer 15 , and pleural mesothelioma 16 .”
BackgroundImmune-related encephalitis after immune checkpoint inhibitor therapy
Buckley, M. W., Balaji, A., Brahmer, J. R., Cappelli, L. C., Sharfman, W. H., Fuchs, E. J., Kang, H., Forde, P. M., Gladstone, D. E., Ambinder, R. F., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae186 · Cited by 41
Choueiri, T. K., Merchan, J. R., Figlin, R. A., McDermott, D. F., Arrowsmith, E. R., Michaelson, M. D., Tykodi, S. S., Heath, E. I., Spigel, D. R., D'souza, A., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00649-1 · Cited by 49
Self-citationFloudas, C. S., Goswami, M., Donahue, R. N., Pastor, D. M., Redman, J. M., Brownell, I., Turkbey, E. B., Cordes, L. M., Steinberg, S. M., Manu, M., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2024.6998 · Cited by 43
Checkpoint Inhibitors in Head and Neck Cancer: Current Knowledge and Perspectives
Samra, B., Tam, E. L., Baseri, B., & Shapira, I. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2018-000743 · Cited by 38
Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies
Solanki, A. A., Bossi, A., Efstathiou, J. A., Lock, D., Mondini, M., Ramapriyan, R., Welsh, J. W., & Kang, J. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.09.013 · Cited by 39
Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors
Youssef, A., Kasso, N., Torloni, A. S., Stanek, M., Dragovich, T., Gimbel, M. I., & Mahmoud, F. A. (2018) · Case Reports in Hematology · doi:10.1155/2018/2464619 · Cited by 38
Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
Bergerot, C. D., Bergerot, P. G., Philip, E. J., Hsu, J., Dizman, N., Vaishampayan, U. N., Dorff, T. B., & Pal, S. K. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0557-5 · Cited by 38
Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma
Barth, D. A., Slabý, O., Klec, C., Juráček, J., Drulă, R., Calin, G. A., & Pichler, M. (2019) · Cancers · doi:10.3390/cancers11101580 · Cited by 38
Graham, J., Shah, A. Y., Wells, J. C., McKay, R. R., Vaishampayan, U. N., Hansen, A. R., Donskov, F. N., Bjarnason, G. A., Beuselinck, B., de Velasco, G., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.11.001 · Cited by 42
Self-citationWang, G., Tai, R., Wu, Y., Yang, S., Wang, J., Yu, X., Lei, L., Shan, Z., & Li, N. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.02.002 · Cited by 38
Dadu, R., Rodgers, T. E., Trinh, V. A., Kemp, E. H., Cubb, T. D., Patel, S. P., Simon, J. M., Burton, E. M., & Tawbi, H. A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000687 · Cited by 38
Yuan, Z., Fernandez, D. C., Dhillon, J., Abraham-Miranda, J., Awasthi, S., Kim, Y., Zhang, J., Jain, R., Serna, A. N., Pow‐Sang, J. M., et al. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0254-y · Cited by 45
Immune classification of clear cell renal cell carcinoma
Su, S., Akbarinejad, S., & Shahriyari, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-83767-z · Cited by 44
Wiele, A. J., Bathala, T. K., Hahn, A. W., Xiao, L., Duran, M., Ross, J. A., Jonasch, E. W., Shah, A. Y., Campbell, M. T., Msaouel, P., et al. (2021) · The Oncologist · doi:10.1002/onco.13770 · Cited by 46
Self-citationPei, X., Zhang, X., Zhang, L., Yuan, M., Sun, L., Yu, F., Wang, B., Zhao, J., He, H., & Yang, V. C.-M. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.129774 · Cited by 41
T-cell Exhaustion in Organ Transplantation
Angeletti, A., Cantarelli, C., Riella, L. V., Fribourg, M., & Cravedi, P. (2021) · Transplantation · doi:10.1097/tp.0000000000003851 · Cited by 39
Msaouel, P., Lee, J., & Thall, P. F. (2021) · Cancers · doi:10.3390/cancers13112741 · Cited by 40
Akhbariyoon, H., Azizpour, Y., Esfahani, M. F., Firoozabad, M. S. M., Rad, M. R., Esfahani, K. S., Khoshavi, N., Karimi, N., Shirinisaz, A., Abedi, F., et al. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108873 · Cited by 41
Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches
Kathuria‐Prakash, N., Drolen, C. E., Hannigan, C. A., & Drakaki, A. (2021) · Life · doi:10.3390/life12010024 · Cited by 41
“The randomized, phase III CheckMate 214 trial assigned patients to receive either a combination of ipilimumab and nivolumab or sunitinib, and the primary outcome was 18-month OS in the patients with intermediate- or poor-risk groups by the International Metastatic RCC Database Consortium (IMDC) [24].”
BackgroundMethodInfluentialIacovelli, R., Ciccarese, C., Facchini, G., Milella, M., Urbano, F., Basso, U., Giorgi, U. D., Sabbatini, R., Santini, D., Berardi, R., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00732-y · Cited by 39
Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy
Yu, A., Dai, X., Wang, Z., Chen, H., Guo, B., & Huang, L. (2022) · Biosensors · doi:10.3390/bios12020109 · Cited by 41
Current Advances in the Management of Adult Craniopharyngiomas
Lara-Velazquez, M. A., Mehkri, Y., Panther, E. J., Hernandez, J. S., Rao, D., Fiester, P. J., Makary, R., Rutenberg, M. S., Tavanaiepour, D., & Rahmathulla, G. (2022) · Current Oncology · doi:10.3390/curroncol29030138 · Cited by 43
Teijeira, Á., Garasa, S., Luri‐Rey, C., de Andrea, C., Gato, M., Molina, C., Kaisho, T., Cirella, A., Azpilikueta, A., Wculek, S. K., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1046 · Cited by 41
Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade
Fitzgerald, K. N., Motzer, R. J., & Lee, C. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00666-2 · Cited by 42
Self-citationGrimm, M.-O., Esteban, E., Barthélémy, P., Schmidinger, M., Busch, J., Valderrama, B. P., Charnley, N., Schmitz, M., Schumacher, U., Leucht, K., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00449-7 · Cited by 37
Self-citationImmunotherapy-induced Hepatotoxicity: A Review
Cunha, T. D., Wu, G. Y., & Vaziri, H. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00105 · Cited by 49
Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
Gebrael, G., Sahu, K. K., Agarwal, N., & Maughan, B. L. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2193528 · Cited by 42
“The CheckMate-214 study investigated the ipilimumab/nivolumab versus sunitinib in treatment-naïve patients with mccRCC.(2) Patients with IMDC favorable-, intermediate-, and poor-risk disease were enrolled (n = 1096).”
MethodDeciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications
Gupta, I., Hussein, O., Sastry, K. S., Bougarn, S., Gopinath, N., Chin-Smith, E. C., Sinha, Y., Korashy, H. M., & Maccalli, C. (2023) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2023.100107 · Cited by 44
Interpreting Randomized Controlled Trials
Msaouel, P., Lee, J., & Thall, P. F. (2023) · Cancers · doi:10.3390/cancers15194674 · Cited by 40
“Nevertheless, it is important to note that these treatment-specific estimates cannot be reliably used to infer the treatment-specific OS outcomes of patient populations [90,91].”
BackgroundTasaki, Y., Sugiyama, Y., Hamamoto, S., Naiki, T., Uemura, T., Yokota, K., Kawakita, D., Nakamura, M., Ogawa, R., Shimura, T., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6724 · Cited by 41
Park, W., & Lopes, G. D. L., Jr. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.12.003 · Cited by 40
Mollica, V., Nunno, V. D., Gatto, L., Santoni, M., Scarpelli, M., Cimadamore, A., Antonio Lopez-beltran, B., Liang Cheng, C., Battelli, N., Montironi, R., et al. (2019) · Cancers · doi:10.3390/cancers11060830 · Cited by 37
“no correlation between PD-L1 expression and survival benefit was observed in patients receiving nivolumab-ipilimumab in Checkmate 214 trial (longer progression-free survival was observed in patients receiving immunotherapy with PD-L1 expression of 1% or more) [21].”
BackgroundImmune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings
Nishida, T., Iijima, H., & Adachi, S. (2019) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v10.i2.17 · Cited by 43
Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Pozzessere, C., Bassanelli, M., Ceribelli, A., Rasul, S., Li, S., Prior, J. O., & Cicone, F. (2019) · Current Urology Reports · doi:10.1007/s11934-019-0938-9 · Cited by 37
NK Cell-Based Immunotherapy in Renal Cell Carcinoma
Terrén, I., Orrantia, A., Mikelez-Alonso, I., Vitallé, J., Zenarruzabeitia, O., & Borrego, F. (2020) · Cancers · doi:10.3390/cancers12020316 · Cited by 41
Mechanisms of Resistance to Checkpoint Blockade Therapy
Shi, H., Lan, J., & Yang, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_5 · Cited by 40
Murakami, T., Tanaka, N., Takamatsu, K., Hakozaki, K., Fukumoto, K., Masuda, T., Mikami, S., Shinojima, T., Kakimi, K., Tsunoda, T., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03006-2 · Cited by 43
Santoni, M., Massari, F., Bracarda, S., Grande, E., Matrana, M. R., Rizzo, M., Giorgi, U. D., Basso, U., Aurilio, G., Incorvaia, L., et al. (2022) · European Urology Focus · doi:10.1016/j.euf.2022.02.004 · Cited by 38
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
Thouvenin, J., Alhalabi, O., Carlo, M. I., Carril-Ajuria, L., Hirsch, L., Chanzá, N. M., Négrier, S., Campedel, L., Martini, D. J., Borchiellini, D., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac158 · Cited by 37
Self-citationMarona, P., Górka, J., Kwapisz, O., Jura, J., Ryś, J., Hoffman, R. M., & Miękus, K. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05251-4 · Cited by 42
Kwok, D. W., & Okada, H. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03450-7 · Cited by 44
Grünwald, V., Powles, T. B., Kopyltsov, E., Kozlov, V. V., Alonso‐Gordoa, T., Eto, M., Hutson, T. E., Motzer, R. J., Winquist, E., Maroto, P., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.01.010 · Cited by 43
“Other studies of ICI combination therapies in a similar population have reported median PFS ranging from 11.1 to 13.8 mo [8,25,26].”
BackgroundMethodInfluentialSelf-citationGravina, A. G., Pellegrino, R., Esposito, A., Cipullo, M., Romeo, M., Palladino, G., Iodice, P., Federico, A., & Troiani, T. (2024) · Cancers · doi:10.3390/cancers16030611 · Cited by 43
“Interestingly, ICI can also be combined, as seen in the case of ipilimumab and nivolumab, for treating different tumour types such as oesophagus [29], lung [30], kidney [31], and melanoma [32].”
BackgroundUllah, I., Rauf, A., Khalil, A. A., Luqman, M., Islam, M. R., Hemeg, H. A., Ahmad, Z., Al-Awthan, Y. S., Bahattab, O. S., & Quradha, M. M. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4112 · Cited by 40
“The high-intensity peak at 1602 cm −1 is related to C = C and C = O vibrations of benzene rings and carbonyl groups of amino acids (Motzer et al., 2018).”
BackgroundMassari, F., Nunno, V. D., Mollica, V., Graham, J., Gatto, L., & Heng, D. Y. C. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.12.011 · Cited by 36
Roviello, G., Corona, S. P., Nesi, G., & Mini, E. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919861905 · Cited by 41
Cost-effectiveness Analysis of 99mTc-sestamibi SPECT/CT to Guide Management of Small Renal Masses
Su, Z. T., Patel, H. D., Huang, M. M., Meyer, A. R., Pavlovich, C. P., Pierorazio, P. M., Javadi, M. S., Allaf, M. E., Rowe, S. P., & Gorin, M. A. (2020) · European Urology Focus · doi:10.1016/j.euf.2020.02.010 · Cited by 37
Efficacy of Immune Checkpoint Inhibitors and Age in Cancer Patients
Huang, X., Gao, P., Song, Y., Sun, J., Chen, X., Zhao, J., & Wang, Z. (2020) · Immunotherapy · doi:10.2217/imt-2019-0124 · Cited by 37
Bergmann, L., Grünwald, V., Maute, L., Grimm, M., Weikert, S., Schleicher, J., Klotz, T., Greiner, J., Flörcken, A., Hartmann, A., et al. (2020) · Oncology Research and Treatment · doi:10.1159/000508450 · Cited by 36
Self-citationWatson, T. R., Gao, X. Y., Reynolds, K. L., & Kong, C. Y. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.16144 · Cited by 43
How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy
Fundytus, A. M., Booth, C. M., & Tannock, I. F. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.208 · Cited by 36
Rizzo, A., Mollica, V., Dall’Olio, F. G., Ricci, A. D., Maggio, I., Marchetti, A., Rosellini, M., Santoni, M., Ardizzoni, A., & Massari, F. (2021) · Future Oncology · doi:10.2217/fon-2021-0069 · Cited by 36
Su, Q., Song, H., Huang, P., Zhang, C., Yang, J., Kong, D., & Wang, W. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.03.041 · Cited by 54
Msaouel, P., Oromendia, C., Siefker-Radtke, A. O., Tannir, N. M., Subudhi, S. K., Gao, J., Wang, Y., Siddiqui, B. A., Shah, A. Y., Aparicio, A. M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.22998 · Cited by 40
Self-citationZheng, K. C., Hai, Y., Chen, H., Zhang, Y., Hu, X., & Ni, K. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05186-8 · Cited by 42
Tannir, N. M., Formiga, M. N., Penkov, K., Kislov, N. V., Vasiliev, A., Skare, N. G., Hong, W., Dai, S., Tang, L., Qureshi, A. H., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02082 · Cited by 41
Self-citationMotzer, R. J., Bex, A., Russo, P., Tomita, Y., Cutuli, H. J., Rojas, C. A., Gross‐Goupil, M., Schinzari, G., Melichar, B., Barthélémy, P., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00773 · Cited by 48
Self-citation
Metadata
- Authors
- Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C. K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M.-O., Bracarda, S., Barrios, C. H., Tomita, Y., Castellano, D., Rini, B. I., Chen, A. C., Mekan, S., McHenry, M. B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H. J., & Escudier, B.
- Affiliations
- Brigham and Women's Hospital (US)
- From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) — both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana–Farber/Harvard Cancer Center (D.F.M.), and Dana–Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman),...
- ORCID
- Motzer, Robert J.
- Tannir, Nizar M.
- McDermott, David F.
- Melichar, Bohuslav
- Choueiri, Toni K.
- Plimack, Elizabeth R.
- Barthélémy, Philippe
- Porta, Camillo
- George, Saby
- Powles, Thomas
- Donskov, Frede
- Kollmannsberger, Christian K.
- Salman, Pamela
- Gurney, Howard
- Ravaud, Alain
- Grimm, Marc-Oliver
- Barrios, Carlos H.
- Tomita, Yoshihiko
- Castellano, Daniel
- Rini, Brian I.
- Mekan, Sabeen
- McHenry, M. Brent
- Sharma, Padmanee
- Hammers, Hans J.
- Escudier, Bernard
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-05
- Volume
- 378
- Issue
- 14
- Pages
- 1277-1290
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5972549
- OpenAlex
- W2792937256
- Cited by
- 4,656
- References
- 31
- Citations by year
- 2026: 305 · 2025: 416 · 2024: 510 · 2023: 601 · 2022: 656 · 2021: 708 · 2020: 684 · 2019: 562 · 2018: 209
- FWCI
- 408.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Ono Pharmaceutical Company Limited
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab plus ipilimumab, sunitinib, advanced renal cell carcinoma, clear cell renal cell carcinoma, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, combination immunotherapy, overall survival, objective response rate, progression-free survival, treatment-related adverse events, immune-related adverse events, first-line therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Sunitinib, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Humans, Indoles, Kidney Neoplasms, Male, Middle Aged, Pyrroles, Quality of Life, Risk, Survival Rate, Survival Analysis, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.